Suba Krishnan
Impact in
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Pancreatic and Hepatic Oncology Research
- Immunology top 5%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Oncology 9
- Cancer Immunotherapy and Biomarkers 7
- CAR-T cell therapy research 3
- PARP inhibition in cancer therapy 2
-
- Blood Coagulation and Thrombosis Mechanisms 4
- Iron Metabolism and Disorders 2
- Co-authors
- Katherine A. Hajjar (2 shared papers)Marc‐Oliver Grimm (1 shared paper)Abdel Saci (1 shared paper)Elizabeth R. Plimack (1 shared paper)Daniel A. Vaena (1 shared paper)Ari David Baron (1 shared paper)Chikara Οhyama (1 shared paper)Andrea Necchi (1 shared paper)
- Journals
- Journal of Clinical Oncology (5 papers)British Journal of Haematology (3 papers)Blood (3 papers)Cancer (1 paper)Clinical Cancer Research (1 paper)
- Partner nations
- United StatesItalyCanada
In The Last Decade
Suba Krishnan
21 papers receiving 2.6k citations
Suba Krishnan's Hit Papers
Peers
Comparison fields: 5 of 83
- Oncology 1.8k
- Immunology 681
- Surgery 1.3k
- Genetics 294
- Hematology 209
Countries citing papers authored by Suba Krishnan
This map shows the geographic impact of Suba Krishnan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suba Krishnan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suba Krishnan more than expected).
Fields of papers citing papers by Suba Krishnan
This network shows the impact of papers produced by Suba Krishnan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suba Krishnan. The network helps show where Suba Krishnan may publish in the future.
Co-authors
The 25 scholars most cited alongside Suba Krishnan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial Hit paper breakdown → | 2017 | 1203 |
| 2 | Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the Hit paper breakdown → | 2020 | 335 |
| 3 | Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody Hit paper breakdown → | 2016 | 281 |
| 4 | 2017 | 137 | |
| 5 | 1999 | 134 | |
| 6 | 2014 | 118 | |
| 7 | 2019 | 92 | |
| 8 | 2021 | 87 | |
| 9 | 2009 | 84 | |
| 10 | 2012 | 56 | |
| 11 | 2011 | 28 | |
| 12 | 2008 | 24 | |
| 13 | 2003 | 17 | |
| 14 | 1998 | 14 | |
| 15 | 2009 | 6 | |
| 16 | 1999 | 3 | |
| 17 | 2024 | 2 | |
| 18 | 2010 | 2 | |
| 19 | 2019 | 2 | |
| 20 | 2022 | 2 |
About Suba Krishnan
Suba Krishnan is a scholar working on Oncology, Hematology, Genetics, Molecular Biology and Surgery, having authored 21 papers that have together received 2.6k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (7 papers), Hemoglobinopathies and Related Disorders (6 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers), Blood Coagulation and Thrombosis Mechanisms (4 papers), CAR-T cell therapy research (3 papers), Iron Metabolism and Disorders (2 papers), PARP inhibition in cancer therapy (2 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (2 papers). The work is most often cited by research in Oncology (1.8k citations), Immunology (681 citations), Surgery (1.3k citations), Genetics (294 citations) and Hematology (209 citations). Suba Krishnan has collaborated with scholars based in United States, Italy and Canada. Frequent co-authors include Katherine A. Hajjar, Marc‐Oliver Grimm, Abdel Saci, Elizabeth R. Plimack, Daniel A. Vaena, Ari David Baron, Chikara Οhyama, Andrea Necchi, Matthew D. Galsky and Padmanee Sharma. Their work appears in journals such as Journal of Clinical Oncology, British Journal of Haematology, Blood, Cancer and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.